Biliary Atresia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major biliary atresia markets are expected to exhibit a CAGR of 5.64% during 2024-2034.
The biliary atresia market has been comprehensively analyzed in IMARC's new report titled "Biliary Atresia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Biliary atresia refers to a rare pediatric liver disease characterized by the progressive obstruction or absence of bile ducts, which carry bile from the liver to the gallbladder and intestines. This condition primarily affects newborns and infants, leading to impaired bile flow, accumulation of bile within the liver, and subsequent liver damage. The symptoms of the ailment typically emerge within a few weeks to months after birth. They often include jaundice, a yellowing of the skin and eyes, dark urine, pale stools, etc. Infants suffering from the disease may also experience poor weight gain, irritability, and abdominal swelling due to an enlarged liver. Diagnosing biliary atresia requires a combination of clinical evaluation, blood tests to assess liver function, and imaging studies, such as ultrasound. Physicians will often recommend a specialized procedure called a cholangiogram, where a contrast dye is injected into the bile ducts to visualize their structure and assess any blockages.
The increasing incidences of infections or genetic predispositions that can cause the immune system to mistakenly attack and destroy the bile ducts, leading to inflammation and obstruction, are primarily driving the biliary atresia market. In addition to this, the inflating utilization of innovative medical approaches, including choleretic agents, nutritional support, and close monitoring, to effectively address symptoms and minimize complications of the disease is also creating a positive outlook for the market. Moreover, the widespread adoption of liver transplantation as a definitive cure for biliary atresia, particularly for patients who do not respond to other conventional treatments, is further bolstering the market growth. Apart from this, the rising popularity of postoperative care, involving the usage of medications like ursodeoxycholic acid to improve bile flow and antibiotics to prevent post-surgical infection, is acting as another significant growth-inducing factor. Additionally, the emerging advancements in surgical techniques, such as hepatoportoenterostomy, which are aimed at re-establishing bile flow from the liver to the intestines, thereby boosting treatment outcomes, are also augmenting the market growth. Furthermore, the escalating application of gene therapy approaches focused on rectifying or replacing defective genes that may be contributing to the pathogenesis of the underlying condition is expected to drive the biliary atresia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the biliary atresia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for biliary atresia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the biliary atresia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the biliary atresia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the biliary atresia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current biliary atresia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the biliary atresia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the biliary atresia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the biliary atresia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of biliary atresia across the seven major markets?
What is the number of prevalent cases (2018-2034) of biliary atresia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of biliary atresia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with biliary atresia across the seven major markets?
What is the size of the biliary atresia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of biliary atresia?
What will be the growth rate of patients across the seven major markets?
Biliary Atresia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for biliary atresia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the biliary atresia market?
What are the key regulatory events related to the biliary atresia market?
What is the structure of clinical trial landscape by status related to the biliary atresia market?
What is the structure of clinical trial landscape by phase related to the biliary atresia market?
What is the structure of clinical trial landscape by route of administration related to the biliary atresia market?
The biliary atresia market has been comprehensively analyzed in IMARC's new report titled "Biliary Atresia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Biliary atresia refers to a rare pediatric liver disease characterized by the progressive obstruction or absence of bile ducts, which carry bile from the liver to the gallbladder and intestines. This condition primarily affects newborns and infants, leading to impaired bile flow, accumulation of bile within the liver, and subsequent liver damage. The symptoms of the ailment typically emerge within a few weeks to months after birth. They often include jaundice, a yellowing of the skin and eyes, dark urine, pale stools, etc. Infants suffering from the disease may also experience poor weight gain, irritability, and abdominal swelling due to an enlarged liver. Diagnosing biliary atresia requires a combination of clinical evaluation, blood tests to assess liver function, and imaging studies, such as ultrasound. Physicians will often recommend a specialized procedure called a cholangiogram, where a contrast dye is injected into the bile ducts to visualize their structure and assess any blockages.
The increasing incidences of infections or genetic predispositions that can cause the immune system to mistakenly attack and destroy the bile ducts, leading to inflammation and obstruction, are primarily driving the biliary atresia market. In addition to this, the inflating utilization of innovative medical approaches, including choleretic agents, nutritional support, and close monitoring, to effectively address symptoms and minimize complications of the disease is also creating a positive outlook for the market. Moreover, the widespread adoption of liver transplantation as a definitive cure for biliary atresia, particularly for patients who do not respond to other conventional treatments, is further bolstering the market growth. Apart from this, the rising popularity of postoperative care, involving the usage of medications like ursodeoxycholic acid to improve bile flow and antibiotics to prevent post-surgical infection, is acting as another significant growth-inducing factor. Additionally, the emerging advancements in surgical techniques, such as hepatoportoenterostomy, which are aimed at re-establishing bile flow from the liver to the intestines, thereby boosting treatment outcomes, are also augmenting the market growth. Furthermore, the escalating application of gene therapy approaches focused on rectifying or replacing defective genes that may be contributing to the pathogenesis of the underlying condition is expected to drive the biliary atresia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the biliary atresia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for biliary atresia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the biliary atresia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the biliary atresia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the biliary atresia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current biliary atresia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the biliary atresia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the biliary atresia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the biliary atresia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of biliary atresia across the seven major markets?
What is the number of prevalent cases (2018-2034) of biliary atresia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of biliary atresia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with biliary atresia across the seven major markets?
What is the size of the biliary atresia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of biliary atresia?
What will be the growth rate of patients across the seven major markets?
Biliary Atresia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for biliary atresia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the biliary atresia market?
What are the key regulatory events related to the biliary atresia market?
What is the structure of clinical trial landscape by status related to the biliary atresia market?
What is the structure of clinical trial landscape by phase related to the biliary atresia market?
What is the structure of clinical trial landscape by route of administration related to the biliary atresia market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BILIARY ATRESIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BILIARY ATRESIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BILIARY ATRESIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BILIARY ATRESIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BILIARY ATRESIA - UNMET NEEDS
10 BILIARY ATRESIA - KEY ENDPOINTS OF TREATMENT
11 BILIARY ATRESIA - MARKETED PRODUCTS
11.1 List of Biliary Atresia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BILIARY ATRESIA - PIPELINE DRUGS
12.1 List of Biliary Atresia Pipeline Drugs Across the Top 7 Markets
12.1.1 Maralixibat - Mirum Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 BILIARY ATRESIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 BILIARY ATRESIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BILIARY ATRESIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Biliary Atresia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Biliary Atresia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Biliary Atresia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Biliary Atresia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Biliary Atresia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Biliary Atresia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Biliary Atresia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Biliary Atresia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Biliary Atresia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Biliary Atresia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Biliary Atresia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Biliary Atresia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Biliary Atresia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Biliary Atresia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Biliary Atresia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Biliary Atresia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Biliary Atresia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Biliary Atresia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Biliary Atresia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Biliary Atresia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Biliary Atresia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Biliary Atresia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Biliary Atresia - Access and Reimbursement Overview
16 BILIARY ATRESIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BILIARY ATRESIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BILIARY ATRESIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BILIARY ATRESIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BILIARY ATRESIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BILIARY ATRESIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BILIARY ATRESIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BILIARY ATRESIA - UNMET NEEDS
10 BILIARY ATRESIA - KEY ENDPOINTS OF TREATMENT
11 BILIARY ATRESIA - MARKETED PRODUCTS
11.1 List of Biliary Atresia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BILIARY ATRESIA - PIPELINE DRUGS
12.1 List of Biliary Atresia Pipeline Drugs Across the Top 7 Markets
12.1.1 Maralixibat - Mirum Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 BILIARY ATRESIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 BILIARY ATRESIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BILIARY ATRESIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Biliary Atresia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Biliary Atresia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Biliary Atresia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Biliary Atresia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Biliary Atresia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Biliary Atresia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Biliary Atresia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Biliary Atresia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Biliary Atresia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Biliary Atresia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Biliary Atresia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Biliary Atresia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Biliary Atresia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Biliary Atresia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Biliary Atresia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Biliary Atresia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Biliary Atresia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Biliary Atresia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Biliary Atresia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Biliary Atresia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Biliary Atresia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Biliary Atresia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Biliary Atresia - Access and Reimbursement Overview
16 BILIARY ATRESIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BILIARY ATRESIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BILIARY ATRESIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
